Valcare Medical

Executive Summary

Valcare Medical is an Israeli medtech company pioneering a transcatheter solution for mitral regurgitation with its AMEND™ platform. The device features a D‑shaped annuloplasty ring equipped with a rapid anchoring system that simultaneously repairs the mitral annulus and serves as a docking station for future valve prostheses. This dual functionality positions AMEND as a versatile tool for both current repair and future valve replacement, addressing a major unmet need in structural heart disease. The company targets the large and growing mitral regurgitation patient population with a minimally invasive approach that could offer shorter recovery times and broader treatability compared to surgical alternatives. Valcare is currently at the preclinical stage, with its technology validated in animal studies. The company has demonstrated the feasibility of its rapid anchoring system and the D‑shaped ring design, which are critical for long‑term durability and procedural simplicity. While no clinical trials have been initiated yet, Valcare’s innovative concept has attracted attention from the interventional cardiology community. The key near‑term catalysts include the start of first‑in‑human studies, securing strategic partnerships, and potential regulatory designations such as CE mark approval. If successful, Valcare could become a leading player in the transcatheter mitral repair market, competing with established technologies like MitraClip and replacing surgical annuloplasty.

Upcoming Catalysts (preview)

• H2 2026Initiation of First-in-Human Clinical Trial60% success
• 2027CE Mark Submission or Breakthrough Device Designation40% success
• H1 2027Strategic Partnership or Licensing Deal50% success